Description
InformationRavoxertinib (GDC-0994) Ravoxertinib (GDC-0994) is a potent, orally available and highly selective ERK1/2 inhibitor with IC50 of 1.1 nM and 0.3 nM, respectively. Phase 1.In vitroGDC-0994 potently inhibits phospho-p90RSK in tumor cells.In vivoGDC-0994 (p.o.) results in significant single-agent activity in multiple in vivo cancer models, including KRAS-mutant and BRAF-mutant human xenograft tumors in mice. In vivo, GDC-0994 (p.o.) inhibits both ERK phosphorylation and activation of ERK-mediated signal transduction pathways, and subsequently prevents ERK-dependent tumor cell proliferation and survival.Cell Datacell lines：MM cells, including INA6, RPMI-8226, U266, and RPMI-Dox40Concentrations：Incubation Time：Powder Purity:≥98%